Logo image of INTS

INTENSITY THERAPEUTICS INC (INTS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:INTS - US45828J1034 - Common Stock

0.3701 USD
-0.01 (-2.66%)
Last: 12/2/2025, 2:58:59 PM
Fundamental Rating

2

Overall INTS gets a fundamental rating of 2 out of 10. We evaluated INTS against 534 industry peers in the Biotechnology industry. INTS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. INTS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year INTS has reported negative net income.
In the past year INTS has reported a negative cash flow from operations.
INTS had negative earnings in each of the past 5 years.
In the past 5 years INTS always reported negative operating cash flow.
INTS Yearly Net Income VS EBIT VS OCF VS FCFINTS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -5M -10M -15M

1.2 Ratios

The Return On Assets of INTS (-122.44%) is worse than 79.59% of its industry peers.
INTS's Return On Equity of -162.50% is on the low side compared to the rest of the industry. INTS is outperformed by 64.04% of its industry peers.
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROIC N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INTS Yearly ROA, ROE, ROICINTS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

INTS does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INTS Yearly Profit, Operating, Gross MarginsINTS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

6

2. Health

2.1 Basic Checks

Compared to 1 year ago, INTS has more shares outstanding
There is no outstanding debt for INTS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
INTS Yearly Shares OutstandingINTS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M 15M
INTS Yearly Total Debt VS Total AssetsINTS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

Based on the Altman-Z score of -8.61, we must say that INTS is in the distress zone and has some risk of bankruptcy.
INTS's Altman-Z score of -8.61 is on the low side compared to the rest of the industry. INTS is outperformed by 70.41% of its industry peers.
INTS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -8.61
ROIC/WACCN/A
WACCN/A
INTS Yearly LT Debt VS Equity VS FCFINTS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 5M -5M 10M -10M -15M

2.3 Liquidity

A Current Ratio of 3.60 indicates that INTS has no problem at all paying its short term obligations.
The Current ratio of INTS (3.60) is comparable to the rest of the industry.
INTS has a Quick Ratio of 3.60. This indicates that INTS is financially healthy and has no problem in meeting its short term obligations.
INTS has a Quick ratio of 3.60. This is comparable to the rest of the industry: INTS outperforms 45.88% of its industry peers.
Industry RankSector Rank
Current Ratio 3.6
Quick Ratio 3.6
INTS Yearly Current Assets VS Current LiabilitesINTS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

1

3. Growth

3.1 Past

INTS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 41.12%, which is quite impressive.
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 15.27% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y60.77%
EPS Next 2Y31.08%
EPS Next 3Y19.3%
EPS Next 5Y15.27%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
INTS Yearly Revenue VS EstimatesINTS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2028 2029 2030 2031 2032 50M 100M 150M 200M 250M
INTS Yearly EPS VS EstimatesINTS Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 -1

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

INTS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year INTS is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INTS Price Earnings VS Forward Price EarningsINTS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INTS Per share dataINTS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as INTS's earnings are expected to grow with 19.30% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y31.08%
EPS Next 3Y19.3%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for INTS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INTENSITY THERAPEUTICS INC

NASDAQ:INTS (12/2/2025, 2:58:59 PM)

0.3701

-0.01 (-2.66%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2025-11-06/amc
Earnings (Next)N/A N/A
Inst Owners4.07%
Inst Owner Change58.89%
Ins Owners11.29%
Ins Owner Change4.01%
Market Cap22.23M
Revenue(TTM)N/A
Net Income(TTM)-11.74M
Analysts80
Price Target2.98 (705.19%)
Short Float %6.67%
Short Ratio0.1
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)34.12%
Min EPS beat(2)32.77%
Max EPS beat(2)35.47%
EPS beat(4)3
Avg EPS beat(4)15.34%
Min EPS beat(4)-10.61%
Max EPS beat(4)35.47%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)3.03%
EPS NQ rev (3m)3.03%
EPS NY rev (1m)0%
EPS NY rev (3m)9.09%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.08
P/tB 3.08
EV/EBITDA N/A
EPS(TTM)-0.63
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.16
OCFYN/A
SpS0
BVpS0.12
TBVpS0.12
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -122.44%
ROE -162.5%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-280.06%
ROA(5y)-210.19%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.6
Quick Ratio 3.6
Altman-Z -8.61
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)41.12%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%76%
EPS Next Y60.77%
EPS Next 2Y31.08%
EPS Next 3Y19.3%
EPS Next 5Y15.27%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y28.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-20.37%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-20.37%
OCF growth 3YN/A
OCF growth 5YN/A

INTENSITY THERAPEUTICS INC / INTS FAQ

What is the fundamental rating for INTS stock?

ChartMill assigns a fundamental rating of 2 / 10 to INTS.


What is the valuation status of INTENSITY THERAPEUTICS INC (INTS) stock?

ChartMill assigns a valuation rating of 0 / 10 to INTENSITY THERAPEUTICS INC (INTS). This can be considered as Overvalued.


How profitable is INTENSITY THERAPEUTICS INC (INTS) stock?

INTENSITY THERAPEUTICS INC (INTS) has a profitability rating of 0 / 10.


What is the financial health of INTENSITY THERAPEUTICS INC (INTS) stock?

The financial health rating of INTENSITY THERAPEUTICS INC (INTS) is 6 / 10.